Twitter-enabled Mobile Messaging for Smoking Relapse Prevention

NCT ID: NCT01602536

Last Updated: 2024-10-31

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We conducted a two-arm (test vs. control, N=160) randomized controlled trial of small, private, online support groups for quitting smoking with 20 people per group who were seeking to quit smoking. A novel feature was a bot (auto-messenger) that posted a daily cessation-related discussion topic in each group, timed to the group's quit date.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Smoking relapse rates remain high, innovative strategies are needed to lower them, and web-based social networking may help like Twitter. This developmental research examined whether providing virtual (web-based) social support to smokers, through Twitter-enabled interactive peer texting, could help smokers quit and avoid relapses. Twitter is a free social networking and micro-blogging service, one of the most advanced and novel technologies available today that can provide social support to smokers, and it provides free texting to groups. It is global and has many features that are associated with treatment success including interactive, multi-way, live messaging and mobile accessibility, because the messages go instantly to mobile phones and to the web. It can provide an innovative way to reach smokers who might otherwise not seek treatment, and it can be extended to other health domains. From June 2012 through 2014, we conducted a two-condition randomized controlled trial. All participants in this trial (N=160) received 8 weeks of free nicotine patches, referral to the NCI's online Smokefree.gov Quit Guide, and instruction to set a quit date within 1 week of study start. Participants were also randomly assigned at the individual level to one of two conditions: (1) a virtual or online quit-smoking group on Twitter where the group members were instructed to use interactive peer messaging to help them quit and stay quit, or (2) a control group condition where the group members were not given this instruction or a Twitter group. In total, there were 4 Twitter groups and 4 control groups with 20 smokers randomly assigned to each group (i.e., N=80 test, N=80 control). In the Twitter groups, a bot (auto-messenger) posted a daily cessation-related discussion topic in each group, timed to the group's quit date. The primary outcome was self-reported 7-day point prevalence abstinence that was sustained at 7, 30 and 60 days after the quit date. Participants' posts, their virtual and face-to-face social networks, and several other possible mediating and moderating variables were also analyzed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Smoking

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Twitter

Experimental participants are assigned a 20-person twitter quit-smoking group to interact with, are instructed to use Twitter-enabled interactive peer messaging,and are sent daily messages to encourage interaction. The baseline intervention 'smoking cessation aides' is also provided.

Group Type EXPERIMENTAL

smoking cessation aides

Intervention Type BEHAVIORAL

All participants will receive 8 weeks of free nicotine patches, referral to the NCI's online Smokefree.gov Quit Guide, and instruction to set a quit date within 8 days of study start.

Twitter

Intervention Type BEHAVIORAL

Twitter quit-smoking group

Control

Control participants are not assigned to a twitter group. The baseline intervention 'smoking cessation aides' is also provided.

Group Type ACTIVE_COMPARATOR

smoking cessation aides

Intervention Type BEHAVIORAL

All participants will receive 8 weeks of free nicotine patches, referral to the NCI's online Smokefree.gov Quit Guide, and instruction to set a quit date within 8 days of study start.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

smoking cessation aides

All participants will receive 8 weeks of free nicotine patches, referral to the NCI's online Smokefree.gov Quit Guide, and instruction to set a quit date within 8 days of study start.

Intervention Type BEHAVIORAL

Twitter

Twitter quit-smoking group

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* must have smoked 100 cigarettes during their lifetime
* must currently smoke 5 or more cigarettes a day
* must be in the preparation stage of quitting smoking
* ages 18-59 years
* English speaking
* have a mobile phone with an unlimited texting plan and internet access
* use text messaging at least once a week
* use Facebook daily
* have an active email account
* live in the continental USA

Exclusion Criteria

* a medical condition that is contra-indicated for nicotine replacement therapy:
* pregnant
* breast feeding
* a recent heart attack
* an irregular heartbeat
* high blood pressure not controlled with medication
* skin allergies to adhesive tape or serious skin problems
* taking a prescription medicine for depression or anxiety
* use drugs or marijuana regularly
* live in the same household with another participant
Minimum Eligible Age

18 Years

Maximum Eligible Age

59 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Drug Abuse (NIDA)

NIH

Sponsor Role collaborator

University of California, Irvine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Cornelia Pechmann

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Cornelia Pechmann, PhD

Role: PRINCIPAL_INVESTIGATOR

University of California, Irvine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hosted Study Website [email protected]

Irvine, California, United States

Site Status

University of California Irvine

Irvine, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Pechmann C, Delucchi K, Lakon CM, Prochaska JJ. Randomised controlled trial evaluation of Tweet2Quit: a social network quit-smoking intervention. Tob Control. 2017 Mar;26(2):188-194. doi: 10.1136/tobaccocontrol-2015-052768. Epub 2016 Feb 29.

Reference Type DERIVED
PMID: 26928205 (View on PubMed)

Pechmann C, Pan L, Delucchi K, Lakon CM, Prochaska JJ. Development of a Twitter-based intervention for smoking cessation that encourages high-quality social media interactions via automessages. J Med Internet Res. 2015 Feb 23;17(2):e50. doi: 10.2196/jmir.3772.

Reference Type DERIVED
PMID: 25707037 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1R34DA030538-01A1

Identifier Type: NIH

Identifier Source: secondary_id

View Link

20107990

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.